Publication Name	World Journal of Clinical Cases
Manuscript ID	39289
Country	Türkiye

Category	Oncology
Manuscript Type	Minireviews
Article Title	Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status
Manuscript Source	Invited Manuscript
All Author List	Ozkan Kanat, Hulya Ertas and Burcu Caner
Funding Agency and Grant Number
Corresponding Author	Ozkan Kanat, MD, PhD, Professor, Department of Medical Oncology, Faculty of Medicine, Uludag University, Gorukle, Bursa 16059, Türkiye. ozkanat@uludag.edu.tr
Key Words	Epidermal growth factor receptor; Cetuximab; Panitumumab; Human epidermal growth factor receptor 2; Anti-epidermal growth factor receptor resistance; Trastuzumab; Dual inhibition
Core Tip	We reviewed the preclinical studies exploring the role of human epidermal growth factor receptor 2 (HER2) signaling in the development of anti-epidermal growth factor receptor therapy resistance in metastatic colorectal cancer and discussed the status of clinical trials assessing the activity of HER2 inhibitors in this setting.
Citation	Kanat O, Ertas H, Caner B. Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status. World J Clin Cases 2018; 6(11): 418-425

Received	2018-04-10 09:50
Peer-Review Started	2018-04-10 10:58
To Make the First Decision	2018-04-27 02:08
Return for Revision	2018-05-15 06:49
Revised	2018-05-15 09:54
Second Decision	2018-06-07 12:08
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2018-06-08 23:35
Articles in Press	2018-06-08 23:35
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2018-09-16 09:10

ISSN	2307-8960 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com